Guggenheim analyst Yatin Suneja downgraded Tourmaline Bio (TRML) to Neutral from Buy after Novartis (NVS) announced a deal to acquire Tourmaline for $48.00 per share in cash. The firm thinks the deal price is “fair” and reflects pharma’s growing interest in both IL-6-targeting antibodies as a target and “the significant market opportunity in cardiovascular disease,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Neutral from Outperform at Wedbush
- Novartis Seals $1.4B Deal with Tourmaline Bio (TRML) to Bolster Heart Disease Portfolio
- Tourmaline Bio Merges with Novartis for $1.4 Billion
- Tourmaline Bio to be acquired by Novartis for $48.00 per share in cash
- Tourmaline Bio’s Promising Drug Developments and Strategic Positioning Make It a Top Pick for 2024